|
Lexicon Pharmaceuticals, Inc. (LXRX) DCF Valuation |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Lexicon Pharmaceuticals, Inc. (LXRX) Bundle
Enhance your investment choices with the (LXRX) DCF Calculator! Review authentic Lexicon Pharmaceuticals financials, adjust growth projections and expenses, and instantly observe how these changes affect the intrinsic value of (LXRX).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.0 | .3 | .1 | 1.2 | 31.1 | 34.8 | 39.0 | 43.6 | 48.9 | 54.7 |
| Revenue Growth, % | 0 | -98.76 | -53.36 | 766.19 | 2481.48 | 11.97 | 11.97 | 11.97 | 11.97 | 11.97 |
| EBITDA | -41.1 | -86.7 | -98.7 | -163.5 | -184.3 | -34.8 | -39.0 | -43.6 | -48.9 | -54.7 |
| EBITDA, % | -171.27 | -29081.88 | -71033.81 | -13576.74 | -592.93 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 2.9 | .3 | .4 | .6 | .5 | 18.0 | 20.1 | 22.5 | 25.2 | 28.2 |
| Depreciation, % | 12.23 | 97.99 | 307.19 | 46.01 | 1.72 | 51.59 | 51.59 | 51.59 | 51.59 | 51.59 |
| EBIT | -44.0 | -87.0 | -99.2 | -164.0 | -184.8 | -34.8 | -39.0 | -43.6 | -48.9 | -54.7 |
| EBIT, % | -183.5 | -29179.87 | -71341.01 | -13622.76 | -594.65 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 152.3 | 86.7 | 138.4 | 170.0 | 238.0 | 34.8 | 39.0 | 43.6 | 48.9 | 54.7 |
| Total Cash, percent | .0 | .0 | .1 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | .4 | .0 | .0 | 1.0 | 3.5 | 8.5 | 9.5 | 10.6 | 11.9 | 13.3 |
| Account Receivables, % | 1.65 | 4.7 | 20.14 | 83.89 | 11.17 | 24.31 | 24.31 | 24.31 | 24.31 | 24.31 |
| Inventories | .0 | .0 | .0 | .4 | .2 | 2.3 | 2.5 | 2.8 | 3.2 | 3.5 |
| Inventories, % | 0.000004167535 | 0 | 0 | 31.64 | 0.74322 | 6.48 | 6.48 | 6.48 | 6.48 | 6.48 |
| Accounts Payable | 5.5 | 9.2 | 10.4 | 14.4 | 14.8 | 25.8 | 28.9 | 32.3 | 36.2 | 40.5 |
| Accounts Payable, % | 22.79 | 3071.14 | 7478.42 | 1195.1 | 47.62 | 74.08 | 74.08 | 74.08 | 74.08 | 74.08 |
| Capital Expenditure | -.1 | -1.2 | -1.3 | -.5 | -1.0 | -16.9 | -18.9 | -21.2 | -23.7 | -26.6 |
| Capital Expenditure, % | -0.36258 | -409.73 | -953.96 | -39.04 | -3.32 | -48.54 | -48.54 | -48.54 | -48.54 | -48.54 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -52.8 | -87.5 | -100.3 | -164.0 | -184.8 | -34.8 | -39.0 | -43.6 | -48.9 | -54.7 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -44.8 | -84.3 | -100.0 | -161.3 | -187.2 | -29.8 | -36.0 | -40.3 | -45.1 | -50.5 |
| WACC, % | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 | 11.14 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -144.6 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -52 | |||||||||
| Terminal Value | -564 | |||||||||
| Present Terminal Value | -333 | |||||||||
| Enterprise Value | -477 | |||||||||
| Net Debt | 42 | |||||||||
| Equity Value | -519 | |||||||||
| Diluted Shares Outstanding, MM | 320 | |||||||||
| Equity Value Per Share | -1.62 |
What You Will Get
- Real Lexicon Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures for Lexicon Pharmaceuticals, Inc. (LXRX).
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates to fit your analysis.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Lexicon's fair value.
- Versatile Excel Template: Designed for quick edits, scenario testing, and detailed projections specific to Lexicon Pharmaceuticals, Inc. (LXRX).
- Time-Saving and Accurate: Avoid building models from scratch while ensuring precision and flexibility in your financial analysis.
Key Features
- 🔍 Real-Life LXRX Financials: Pre-filled historical and projected data for Lexicon Pharmaceuticals, Inc.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Lexicon’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Lexicon’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Download the Template: Gain immediate access to the Excel-based LXRX DCF Calculator.
- Input Your Assumptions: Modify the yellow-highlighted cells for growth rates, WACC, margins, and other variables.
- Instant Calculations: The model automatically recalculates Lexicon Pharmaceuticals' intrinsic value.
- Test Scenarios: Experiment with various assumptions to assess potential changes in valuation.
- Analyze and Decide: Leverage the results to inform your investment or financial strategy.
Why Choose This Calculator for Lexicon Pharmaceuticals, Inc. (LXRX)?
- Accuracy: Utilizes real Lexicon financial data for precise calculations.
- Flexibility: Allows users to easily adjust and test various inputs.
- Time-Saving: Avoid the complexity of constructing a DCF model from the ground up.
- Professional-Grade: Engineered with the expertise and usability expected by finance professionals.
- User-Friendly: Intuitive design ensures accessibility for users without extensive financial modeling skills.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing investments in Lexicon Pharmaceuticals (LXRX).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decision-making within the organization.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Lexicon Pharmaceuticals (LXRX).
- Students and Educators: Utilize real-world data to learn and teach financial modeling techniques related to the pharmaceutical industry.
- Healthcare Analysts: Gain insights into how biotech firms like Lexicon Pharmaceuticals (LXRX) are valued in the market.
What the Template Contains
- Pre-Filled DCF Model: Lexicon Pharmaceuticals’ (LXRX) financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Lexicon Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.